Kyowa Kirin Co Ltd (JP:4151)
:4151
Want to see JP:4151 full AI Analyst Report?
Top Page
Kyowa Kirin Co
(4151)
Select Model
Select Model
Rating:69Neutral
Price Target:
¥2,547.00
▼(-1.49% Downside)
Action:Downgraded
Date:05/09/26
The score is primarily supported by strong financial fundamentals (high profitability, very low leverage, and improved free cash flow). Offsetting this, technical signals are notably weak (below major moving averages with negative MACD), while valuation is mixed with a supportive dividend but a relatively high P/E.
Positive Factors
Conservative Balance Sheet
Extremely low leverage and a large equity base provide durable financial flexibility. Over the next 2–6 months this supports continued R&D funding, resilience to revenue variability, and optionality for licensing, M&A or shareholder distributions without stressing liquidity or credit profiles.
Negative Factors
Modest Revenue Growth
Top-line growth of roughly 3% indicates limited organic expansion from existing products. Over 2–6 months this constrains the pace at which operating leverage and earnings can scale, increasing dependence on new indications, launches, or partnerships to drive meaningful revenue uplift.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative Balance Sheet
Extremely low leverage and a large equity base provide durable financial flexibility. Over the next 2–6 months this supports continued R&D funding, resilience to revenue variability, and optionality for licensing, M&A or shareholder distributions without stressing liquidity or credit profiles.
Read all positive factors
Kyowa Kirin Co (4151) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥1.29T
Dividend Yield2.33%
Average Volume (3M)1.20M
Price to Earnings (P/E)18.0
Beta (1Y)0.51
Revenue Growth3.20%
EPS Growth43.05%
CountryJP
Employees5,669
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)139.28
Shares Outstanding525,634,500
10 Day Avg. Volume1,064,410
30 Day Avg. Volume1,199,913
Financial Highlights & Ratios
PEG Ratio1.49
Price to Book (P/B)1.48
Price to Sales (P/S)2.66
P/FCF Ratio22.46
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥1,833.33Price Target Upside-29.09% Downside
Rating ConsensusStrong Sell
Number of Analyst Covering3
EPS Forecast (FY)158.58
Revenue Forecast (FY)¥523.38B
Kyowa Kirin Co Business Overview & Revenue Model
Company Description
Kyowa Kirin Co., Ltd. manufactures and markets pharmaceuticals that focuses on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide. Its products include ABSTRAL, a sublingual formulation of fentanyl used...
How the Company Makes Money
Kyowa Kirin primarily makes money by selling prescription pharmaceuticals. Revenue is generated mainly from: (1) Product sales of branded medicines: Kyowa Kirin manufactures and/or distributes its therapies and recognizes revenue from sales to who...
Kyowa Kirin Co Earnings Call Summary
Earnings Call Date:Jul 31, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Jul 30, 2026
Earnings Call Sentiment Neutral
The earnings call highlighted significant growth in North American and EMEA markets, particularly in strategic products like Crysvita and Poteligeo. However, this was offset by declines in overall revenue and interim profit due to restructuring costs and challenges in the Japanese market. While there were strong performances in certain segments and promising R&D developments, the financial declines and restructuring challenges resulted in a mixed sentiment.Positive Updates
Growth in North America and EMEA
Sales in North America increased by JPY9.6 billion, or 12%, in real terms excluding forex impact. Crysvita and Poteligeo grew 11% and 15% respectively in local currency terms.
Negative Updates
Overall Revenue and Profit Decline
Revenue was JPY230.7 billion, a decrease of JPY.3 billion, or 1%. Core operating profit was JPY35 billion, a decrease of JPY9.1 billion, or 21%, and interim profit was JPY16.3 billion, a decrease of JPY21.5 billion, or 57%.
Read all updates
Q2-2025 Updates
Positive
Negative
Growth in North America and EMEA
Sales in North America increased by JPY9.6 billion, or 12%, in real terms excluding forex impact. Crysvita and Poteligeo grew 11% and 15% respectively in local currency terms.
Read all positive updates
Company Guidance
During the call, Kyowa Kirin Co., Ltd. provided financial guidance for Q2 of the fiscal year ending December 31, 2025. The company reported a revenue of JPY230.7 billion, marking a 1% decrease compared to the previous year, largely due to business restructuring in the APAC region and NHI price reductions in Japan. Core operating profit fell by 21% to JPY35 billion, attributed to a decrease in gross profit and a 7% rise in R&D expenses. Interim profit saw a significant drop of 57% to JPY16.3 billion, impacted by JPY9.4 billion in special voluntary retirement payments. Despite these declines, the company remains optimistic about achieving its full-year plan, with revenue and gross profit at 48% of the forecast and core operating profit at 44%. Sales in North America grew by 12%, driven by Crysvita and Poteligeo, which saw increases of 11% and 15%, respectively. The company is also advancing its R&D pipeline, with promising developments in products like Ziftomenib and rocatinlimab, which are undergoing crucial trials and FDA submissions.Kyowa Kirin Co Financial Statement Overview
Summary
Income Statement
82
Very Positive
Balance Sheet
90
Very Positive
Cash Flow
84
Very Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 510.57B | 496.83B | 495.56B | 442.23B | 398.37B | 352.25B |
| Gross Profit | 374.22B | 356.35B | 351.22B | 320.62B | 301.36B | 253.89B |
| EBITDA | 137.66B | 128.42B | 116.65B | 116.94B | 100.85B | 80.61B |
| Net Income | 72.91B | 67.04B | 59.87B | 81.19B | 53.57B | 52.35B |
Balance Sheet | ||||||
| Total Assets | 1.07T | 1.11T | 1.07T | 1.03T | 939.88B | 921.87B |
| Cash, Cash Equivalents and Short-Term Investments | 249.52B | 218.77B | 244.68B | 403.08B | 339.19B | 335.08B |
| Total Debt | 21.72B | 26.13B | 21.68B | 19.70B | 22.29B | 16.59B |
| Total Liabilities | 174.42B | 214.53B | 216.55B | 189.52B | 177.06B | 184.71B |
| Stockholders Equity | 892.74B | 893.33B | 850.81B | 836.42B | 762.83B | 737.16B |
Cash Flow | ||||||
| Free Cash Flow | 107.78B | 58.90B | 41.85B | 98.34B | 33.11B | 80.03B |
| Operating Cash Flow | 145.55B | 96.62B | 67.88B | 115.55B | 48.67B | 86.55B |
| Investing Cash Flow | -83.97B | -89.19B | -142.39B | -20.38B | -17.18B | -11.36B |
| Financing Cash Flow | -38.26B | -36.85B | -84.70B | -32.53B | -29.03B | -28.45B |
Kyowa Kirin Co Technical Analysis
Positive
2585.50
Price Trends
2449.79
Positive
2490.04
Positive
2472.69
Positive
Market Momentum
1.99
Negative
60.69
Neutral
81.17
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4151, the sentiment is Positive. The current price of 2585.5 is above the 20-day moving average (MA) of 2386.92, above the 50-day MA of 2449.79, and above the 200-day MA of 2472.69, indicating a bullish trend. The MACD of 1.99 indicates Negative momentum. The RSI at 60.69 is Neutral, neither overbought nor oversold. The STOCH value of 81.17 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4151.
Kyowa Kirin Co Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | ¥1.13T | 16.15 | 6.03% | 3.63% | 5.94% | 39.34% | |
72 Outperform | ¥12.74T | 28.72 | 22.23% | 1.17% | 5.65% | 10.24% | |
69 Neutral | ¥1.29T | 17.99 | 4.27% | 2.33% | 3.20% | 43.05% | |
65 Neutral | ¥3.82T | 14.06 | 7.97% | 3.61% | 11.87% | 474.27% | |
65 Neutral | ¥1.10T | 29.13 | 5.75% | 3.51% | 4.56% | -16.55% | |
61 Neutral | ¥4.96T | 19.08 | 18.56% | 2.07% | 12.55% | -10.18% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
JP:4151
Kyowa Kirin Co
2,505.00
208.98
9.10%
JP:4503
Astellas Pharma
2,283.00
908.75
66.13%
JP:4519
Chugai Pharmaceutical Co
7,892.00
564.36
7.70%
JP:4568
Daiichi Sankyo Company
2,700.50
-1,046.19
-27.92%
JP:4523
Eisai Co
3,984.00
-26.33
-0.66%
JP:4528
ONO Pharmaceutical Co
2,392.50
887.34
58.95%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.